Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients

Graham H.R. Smith, Mohamed Rachid Boulassel, Marina Klien, Nobert Gilmore, Jean MacLeod, Roger LeBlanc, Pierre René, Jean Pierre Routy, Richard G. Lalonde

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose: To assess the virologic and immunologic response to a boosted double-protease inhibitor (PI) regimen of highly pretreated patients infected with HIV-1 and to examine the role of PI resistance and concentration of serum saquinavir. Method: In an open-label prospective study, lopinavir/ritonavir, saquinavir-sgc, lamivudine, and other nucleoside analogues were offered to highly pretreated patients who had advanced HIV-1 infection and who had failed at least 2 previous highly active antiretroviral therapy regimens including at least 1 nonnucleoside reverse transcriptase inhibitor. The relationship between baseline drug resistance and steady-state saquinavir serum levels and early (week 4) and sustained (week 48) virologic response was documented. Results: 35 advanced HIV-1 patients were enrolled. The boosted double-PI regimen was well tolerated. Twenty-two (63%) of the 35 patients had a > 0.8 log10 decrease in HIV viral load at week 4. After 48 weeks of follow-up, the 22 patients who remained on the study therapy had an average decrease in viral load of 1 log10 and had a median increase in CD4 cells of 60 cell/μL. Multiple logistic regression analysis indicated that genotypic resistance to both PIs and the week-3 trough concentrations of saquinavir were associated with virologic outcome at week 4. The presence of ≥6 lopinavir mutations [odds ratio (OR) 0.03; 95% CI 0.01 to 0.79] and the 48V mutation (OR 0.01; 95%CI <0.01 to 0.88) was independently associated with lower odds of achieving an early response, whereas a higher saquinavir concentration at week 3 (OR 8.36; 95% CI 1.28 to 54.70) was associated with greater odds of an early response. Conclusion: These findings suggest that baseline PI resistance and saquinavir concentration were associated with virologic response and should be considered when planning salvage therapy.

Original languageEnglish
Pages (from-to)63-72
Number of pages10
JournalHIV Clinical Trials
Volume6
Issue number2
DOIs
Publication statusPublished - Mar 2005

Fingerprint

Saquinavir
Protease Inhibitors
HIV-1
Lopinavir
Odds Ratio
Viral Load
Therapeutics
Ritonavir
Salvage Therapy
Mutation
Reverse Transcriptase Inhibitors
Lamivudine
Highly Active Antiretroviral Therapy
Serum
Nucleosides
Drug Resistance
HIV Infections
Logistic Models
Regression Analysis
HIV

Keywords

  • Boosted double-protease regimen
  • HIV resistance
  • Pharmacokinetics
  • Salvage therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients. / Smith, Graham H.R.; Boulassel, Mohamed Rachid; Klien, Marina; Gilmore, Nobert; MacLeod, Jean; LeBlanc, Roger; René, Pierre; Routy, Jean Pierre; Lalonde, Richard G.

In: HIV Clinical Trials, Vol. 6, No. 2, 03.2005, p. 63-72.

Research output: Contribution to journalArticle

Smith, Graham H.R. ; Boulassel, Mohamed Rachid ; Klien, Marina ; Gilmore, Nobert ; MacLeod, Jean ; LeBlanc, Roger ; René, Pierre ; Routy, Jean Pierre ; Lalonde, Richard G. / Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients. In: HIV Clinical Trials. 2005 ; Vol. 6, No. 2. pp. 63-72.
@article{f3439586cb4940fda7b8df020c357759,
title = "Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients",
abstract = "Purpose: To assess the virologic and immunologic response to a boosted double-protease inhibitor (PI) regimen of highly pretreated patients infected with HIV-1 and to examine the role of PI resistance and concentration of serum saquinavir. Method: In an open-label prospective study, lopinavir/ritonavir, saquinavir-sgc, lamivudine, and other nucleoside analogues were offered to highly pretreated patients who had advanced HIV-1 infection and who had failed at least 2 previous highly active antiretroviral therapy regimens including at least 1 nonnucleoside reverse transcriptase inhibitor. The relationship between baseline drug resistance and steady-state saquinavir serum levels and early (week 4) and sustained (week 48) virologic response was documented. Results: 35 advanced HIV-1 patients were enrolled. The boosted double-PI regimen was well tolerated. Twenty-two (63{\%}) of the 35 patients had a > 0.8 log10 decrease in HIV viral load at week 4. After 48 weeks of follow-up, the 22 patients who remained on the study therapy had an average decrease in viral load of 1 log10 and had a median increase in CD4 cells of 60 cell/μL. Multiple logistic regression analysis indicated that genotypic resistance to both PIs and the week-3 trough concentrations of saquinavir were associated with virologic outcome at week 4. The presence of ≥6 lopinavir mutations [odds ratio (OR) 0.03; 95{\%} CI 0.01 to 0.79] and the 48V mutation (OR 0.01; 95{\%}CI <0.01 to 0.88) was independently associated with lower odds of achieving an early response, whereas a higher saquinavir concentration at week 3 (OR 8.36; 95{\%} CI 1.28 to 54.70) was associated with greater odds of an early response. Conclusion: These findings suggest that baseline PI resistance and saquinavir concentration were associated with virologic response and should be considered when planning salvage therapy.",
keywords = "Boosted double-protease regimen, HIV resistance, Pharmacokinetics, Salvage therapy",
author = "Smith, {Graham H.R.} and Boulassel, {Mohamed Rachid} and Marina Klien and Nobert Gilmore and Jean MacLeod and Roger LeBlanc and Pierre Ren{\'e} and Routy, {Jean Pierre} and Lalonde, {Richard G.}",
year = "2005",
month = "3",
doi = "10.1310/HAG3-8YA5-UDQC-36NX",
language = "English",
volume = "6",
pages = "63--72",
journal = "HIV Clinical Trials",
issn = "1528-4336",
publisher = "Thomas Land Publishers Inc.",
number = "2",

}

TY - JOUR

T1 - Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients

AU - Smith, Graham H.R.

AU - Boulassel, Mohamed Rachid

AU - Klien, Marina

AU - Gilmore, Nobert

AU - MacLeod, Jean

AU - LeBlanc, Roger

AU - René, Pierre

AU - Routy, Jean Pierre

AU - Lalonde, Richard G.

PY - 2005/3

Y1 - 2005/3

N2 - Purpose: To assess the virologic and immunologic response to a boosted double-protease inhibitor (PI) regimen of highly pretreated patients infected with HIV-1 and to examine the role of PI resistance and concentration of serum saquinavir. Method: In an open-label prospective study, lopinavir/ritonavir, saquinavir-sgc, lamivudine, and other nucleoside analogues were offered to highly pretreated patients who had advanced HIV-1 infection and who had failed at least 2 previous highly active antiretroviral therapy regimens including at least 1 nonnucleoside reverse transcriptase inhibitor. The relationship between baseline drug resistance and steady-state saquinavir serum levels and early (week 4) and sustained (week 48) virologic response was documented. Results: 35 advanced HIV-1 patients were enrolled. The boosted double-PI regimen was well tolerated. Twenty-two (63%) of the 35 patients had a > 0.8 log10 decrease in HIV viral load at week 4. After 48 weeks of follow-up, the 22 patients who remained on the study therapy had an average decrease in viral load of 1 log10 and had a median increase in CD4 cells of 60 cell/μL. Multiple logistic regression analysis indicated that genotypic resistance to both PIs and the week-3 trough concentrations of saquinavir were associated with virologic outcome at week 4. The presence of ≥6 lopinavir mutations [odds ratio (OR) 0.03; 95% CI 0.01 to 0.79] and the 48V mutation (OR 0.01; 95%CI <0.01 to 0.88) was independently associated with lower odds of achieving an early response, whereas a higher saquinavir concentration at week 3 (OR 8.36; 95% CI 1.28 to 54.70) was associated with greater odds of an early response. Conclusion: These findings suggest that baseline PI resistance and saquinavir concentration were associated with virologic response and should be considered when planning salvage therapy.

AB - Purpose: To assess the virologic and immunologic response to a boosted double-protease inhibitor (PI) regimen of highly pretreated patients infected with HIV-1 and to examine the role of PI resistance and concentration of serum saquinavir. Method: In an open-label prospective study, lopinavir/ritonavir, saquinavir-sgc, lamivudine, and other nucleoside analogues were offered to highly pretreated patients who had advanced HIV-1 infection and who had failed at least 2 previous highly active antiretroviral therapy regimens including at least 1 nonnucleoside reverse transcriptase inhibitor. The relationship between baseline drug resistance and steady-state saquinavir serum levels and early (week 4) and sustained (week 48) virologic response was documented. Results: 35 advanced HIV-1 patients were enrolled. The boosted double-PI regimen was well tolerated. Twenty-two (63%) of the 35 patients had a > 0.8 log10 decrease in HIV viral load at week 4. After 48 weeks of follow-up, the 22 patients who remained on the study therapy had an average decrease in viral load of 1 log10 and had a median increase in CD4 cells of 60 cell/μL. Multiple logistic regression analysis indicated that genotypic resistance to both PIs and the week-3 trough concentrations of saquinavir were associated with virologic outcome at week 4. The presence of ≥6 lopinavir mutations [odds ratio (OR) 0.03; 95% CI 0.01 to 0.79] and the 48V mutation (OR 0.01; 95%CI <0.01 to 0.88) was independently associated with lower odds of achieving an early response, whereas a higher saquinavir concentration at week 3 (OR 8.36; 95% CI 1.28 to 54.70) was associated with greater odds of an early response. Conclusion: These findings suggest that baseline PI resistance and saquinavir concentration were associated with virologic response and should be considered when planning salvage therapy.

KW - Boosted double-protease regimen

KW - HIV resistance

KW - Pharmacokinetics

KW - Salvage therapy

UR - http://www.scopus.com/inward/record.url?scp=25144451316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25144451316&partnerID=8YFLogxK

U2 - 10.1310/HAG3-8YA5-UDQC-36NX

DO - 10.1310/HAG3-8YA5-UDQC-36NX

M3 - Article

VL - 6

SP - 63

EP - 72

JO - HIV Clinical Trials

JF - HIV Clinical Trials

SN - 1528-4336

IS - 2

ER -